Immune checkpoint inhibitors have shown promise in treating advanced non-small cell lung cancer and have a solid safety profile.
Cemiplimab can be used as monotherapy or in combination with chemotherapy for both squamous and non-squamous cancers.
We opted for a systematic review and meta-analysis to find out the efficacy outcome and safety profile along with quality-of-life data of cemiplimab for advanced non-small-cell lung cancer (NSCLC).
